These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

844 related articles for article (PubMed ID: 25667169)

  • 1. Development of novel antibacterial drugs to combat multiple resistant organisms.
    Bassetti M; Righi E
    Langenbecks Arch Surg; 2015 Feb; 400(2):153-65. PubMed ID: 25667169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New antibiotics for bad bugs: where are we?
    Bassetti M; Merelli M; Temperoni C; Astilean A
    Ann Clin Microbiol Antimicrob; 2013 Aug; 12():22. PubMed ID: 23984642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections.
    Bassetti M; Righi E
    Curr Opin Crit Care; 2015 Oct; 21(5):402-11. PubMed ID: 26263298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial resistance and treatment: an unmet clinical safety need.
    Bassetti M; Russo A; Carnelutti A; La Rosa A; Righi E
    Expert Opin Drug Saf; 2018 Jul; 17(7):669-680. PubMed ID: 29897796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The β-Lactams Strike Back: Ceftazidime-Avibactam.
    Zasowski EJ; Rybak JM; Rybak MJ
    Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management.
    Kaye KS; Pogue JM
    Pharmacotherapy; 2015 Oct; 35(10):949-62. PubMed ID: 26497481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug-Resistant and Virulent Organisms Trauma Infections: Trauma Infectious Disease Outcomes Study Initiative.
    Mende K; Akers KS; Tyner SD; Bennett JW; Simons MP; Blyth DM; Li P; Stewart L; Tribble DR
    Mil Med; 2022 May; 187(Suppl 2):42-51. PubMed ID: 35512375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
    Liscio JL; Mahoney MV; Hirsch EB
    Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversing resistance: The next generation antibacterials.
    Shah NJ
    Indian J Pharmacol; 2015; 47(3):248-55. PubMed ID: 26069360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant Enterococcus: Three major threats to hematopoietic stem cell transplant recipients.
    Satlin MJ; Walsh TJ
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28815897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cephalosporins currently in early clinical trials for the treatment of bacterial infections.
    Long TE; Williams JT
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1375-87. PubMed ID: 24956017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in antibacterial therapy against emerging bacterial pathogens.
    Pournaras S; Iosifidis E; Roilides E
    Semin Hematol; 2009 Jul; 46(3):198-211. PubMed ID: 19549574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antimicrobial armamentarium: evaluating current and future treatment options.
    Bosso JA
    Pharmacotherapy; 2005 Oct; 25(10 Pt 2):55S-62S. PubMed ID: 16178676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surveillance and management of multidrug-resistant microorganisms.
    Orsi GB; Falcone M; Venditti M
    Expert Rev Anti Infect Ther; 2011 Aug; 9(8):653-79. PubMed ID: 21819331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogens.
    Poulakou G; Giamarellou H
    Expert Opin Investig Drugs; 2008 May; 17(5):749-71. PubMed ID: 18447600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidrug-resistant gram-negative infections. Bringing back the old.
    Chan-Tompkins NH
    Crit Care Nurs Q; 2011; 34(2):87-100. PubMed ID: 21407003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The current state of multidrug-resistant gram-negative bacilli in North America.
    Nicasio AM; Kuti JL; Nicolau DP
    Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance.
    Syue LS; Chen YH; Ko WC; Hsueh PR
    Int J Antimicrob Agents; 2016 Apr; 47(4):250-8. PubMed ID: 27005457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug-Resistant Gram-Negative Bacterial Infections in the Hospital Setting: Overview, Implications for Clinical Practice, and Emerging Treatment Options.
    Cerceo E; Deitelzweig SB; Sherman BM; Amin AN
    Microb Drug Resist; 2016 Jul; 22(5):412-31. PubMed ID: 26866778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.